The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $7.22 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The expansion in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development.
The viral and non-viral vector manufacturing market size is expected to see rapid growth in the next few years. It will grow to $17.85 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The anticipated increase during the forecast period can be ascribed to the increasing need for gene therapies, the broader utilization of treatments for rare diseases, heightened investments in biomanufacturing infrastructure, and the growing acceptance of precision medicine. Notable trends expected in the forecast period encompass the progression of next-generation viral vectors, a heightened utilization of CRISPR/Cas9 technology in vector manufacturing, an emphasis on scalable and cost-efficient manufacturing processes, a rising adoption of non-viral vectors, and advancements in technologies for manufacturing cell and gene therapies.
The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.
The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.
A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.
Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.
In January 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A. for $874.5 million, aiming to enhance its global capacity for cell and gene therapies and vaccines. Henogen S.A., a biomanufacturing company based in Belgium, provides bioprocess development and viral vector manufacturing services, exemplifying the strategic moves within the industry to expand capabilities and meet growing demands.
Major companies operating in the viral and non-viral vector manufacturing market report are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
North America was the largest region in the viral and non-viral vector manufacturing market in 2023. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.
The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The viral and non-viral vector manufacturing market size is expected to see rapid growth in the next few years. It will grow to $17.85 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The anticipated increase during the forecast period can be ascribed to the increasing need for gene therapies, the broader utilization of treatments for rare diseases, heightened investments in biomanufacturing infrastructure, and the growing acceptance of precision medicine. Notable trends expected in the forecast period encompass the progression of next-generation viral vectors, a heightened utilization of CRISPR/Cas9 technology in vector manufacturing, an emphasis on scalable and cost-efficient manufacturing processes, a rising adoption of non-viral vectors, and advancements in technologies for manufacturing cell and gene therapies.
The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.
The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.
A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.
Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.
In January 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A. for $874.5 million, aiming to enhance its global capacity for cell and gene therapies and vaccines. Henogen S.A., a biomanufacturing company based in Belgium, provides bioprocess development and viral vector manufacturing services, exemplifying the strategic moves within the industry to expand capabilities and meet growing demands.
Major companies operating in the viral and non-viral vector manufacturing market report are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
North America was the largest region in the viral and non-viral vector manufacturing market in 2023. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.
The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Viral and Non-Viral Vector Manufacturing Market Characteristics3. Viral and Non-Viral Vector Manufacturing Market Trends and Strategies32. Global Viral and Non-Viral Vector Manufacturing Market Competitive Benchmarking33. Global Viral and Non-Viral Vector Manufacturing Market Competitive Dashboard34. Key Mergers and Acquisitions in the Viral and Non-Viral Vector Manufacturing Market
4. Viral and Non-Viral Vector Manufacturing Market - Macro Economic Scenario
5. Global Viral and Non-Viral Vector Manufacturing Market Size and Growth
6. Viral and Non-Viral Vector Manufacturing Market Segmentation
7. Viral and Non-Viral Vector Manufacturing Market Regional and Country Analysis
8. Asia-Pacific Viral and Non-Viral Vector Manufacturing Market
9. China Viral and Non-Viral Vector Manufacturing Market
10. India Viral and Non-Viral Vector Manufacturing Market
11. Japan Viral and Non-Viral Vector Manufacturing Market
12. Australia Viral and Non-Viral Vector Manufacturing Market
13. Indonesia Viral and Non-Viral Vector Manufacturing Market
14. South Korea Viral and Non-Viral Vector Manufacturing Market
15. Western Europe Viral and Non-Viral Vector Manufacturing Market
16. UK Viral and Non-Viral Vector Manufacturing Market
17. Germany Viral and Non-Viral Vector Manufacturing Market
18. France Viral and Non-Viral Vector Manufacturing Market
19. Italy Viral and Non-Viral Vector Manufacturing Market
20. Spain Viral and Non-Viral Vector Manufacturing Market
21. Eastern Europe Viral and Non-Viral Vector Manufacturing Market
22. Russia Viral and Non-Viral Vector Manufacturing Market
23. North America Viral and Non-Viral Vector Manufacturing Market
24. USA Viral and Non-Viral Vector Manufacturing Market
25. Canada Viral and Non-Viral Vector Manufacturing Market
26. South America Viral and Non-Viral Vector Manufacturing Market
27. Brazil Viral and Non-Viral Vector Manufacturing Market
28. Middle East Viral and Non-Viral Vector Manufacturing Market
29. Africa Viral and Non-Viral Vector Manufacturing Market
30. Viral and Non-Viral Vector Manufacturing Market Competitive Landscape and Company Profiles
31. Viral and Non-Viral Vector Manufacturing Market Other Major and Innovative Companies
35. Viral and Non-Viral Vector Manufacturing Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Viral and Non-Viral Vector Manufacturing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on viral and non-viral vector manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for viral and non-viral vector manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Vector Type: Viral Vector; Non-Viral Vector
2) By Disease: Cancer; Genetic Disease; Infectious Disease; Cardiovascular Disease; Other Diseases
3) By Application: Gene Therapy; Vaccinology; Cell Therapy; Other Applications
Key Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; Merck KGaA; FUJIFILM Holdings Corporation; Regeneron Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Novartis AG
- Thermo Fisher Scientific Inc.
- Merck KGaA
- FUJIFILM Holdings Corporation
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Lonza Group AG
- WuXi AppTec Co Ltd.
- Catalent Inc.
- Sartorius AG
- Charles River Laboratories Inc.
- Sarepta Therapeutics Inc.
- GenScript ProBio Co. Ltd.
- TAKARA BIO Inc.
- Oxford BioMedica plc
- Beam Therapeutics Inc.
- Intellia Therapeutics Inc.
- MaxCyte Inc.
- Voyager Therapeutics Inc.
- Genethon
- MeiraGTx Holdings plc
- Evox Therapeutics Ltd.
- Entos Pharmaceuticals Inc.
- LogicBio Therapeutics Inc.
- bluebird bio Inc.
- 4D Molecular Therapeutics Inc.
- Precision NanoSystems Inc.
- GenSight Biologics S.A.
- Abeona Therapeutics Inc.
- Generation Bio Co.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 8.62 Billion |
| Forecasted Market Value ( USD | $ 17.85 Billion |
| Compound Annual Growth Rate | 20.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
